Hofseth Biocare ASA: CHANGES IN BOARD OF DIRECTORS - OLA HOLEN TO FUNCTION AS NEW INTERIM CHAIRMAN
September 15 2017 - 2:25AM
Reference is made to the
stock exchange notice dated 14 August 2017, whereby it was informed
that Tor Erik Andersen had resigned from the position as CEO of the
Company and Roger Hofseth had assumed the position as CEO.
As a consequence of this,
the board of directors (the "Board") of Hofseth BioCare ASA ("HBC"
or the "Company") has today accepted Roger Hofseth's resignation as
chairman of the Board. Deputy director Ola Holen will function as
the chairman of the Board until a new chairman of the Board may be
elected.
The Board is very satisfied
that Mr. Holen, with his broad experience from the fish processing
industry, will function as interim chairman going forward.
For further information,
please contact:
Roger Hofseth, CEO of
Hofseth BioCare ASA
Mob: +47 95147941
E-mail: rh@hofseth-as.no
Jon Olav Ødegård, CFO of
Hofseth BioCare ASA
Mob: +47 93632966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare
ASA:
HBC is a Norwegian biotech
company that offers high-value ingredients and finished products
for humans and pets. The company is founded on the core values of
sustainability, traceability and optimal utilization of natural
resources. Through an innovative hydrolysis technology, HBC is able
to preserve the quality of salmon oil, proteins and calcium,
prepared of fresh salmon off-cuts. HBC's objective is to contribute
to the efficient use of marine resources and deliver quality
products for ingredients and finished consumer products in the
nutrition market. Hofseth BioCare's headquarters are located in
Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo.
HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC".
More information about Hofseth BioCare at www.hofsethbiocare.com
and www.facebook.com/hofsethbiocare
This information is subject
to the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Hofseth Biocare ASA via Globenewswire